Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalPediatricsMalnutritionTrial Update

Trial of SMS Platform to Prevent Malnutrition in HIV-Exposed Children in Kenya

This trial represents a significant step in leveraging digital health interventions to address malnutrition among vulnerable populations. Its outcomes could reshape investment strategies in pediatric care and digital health solutions, particularly in low-resource settings.

Published: June 20, 2026
Updated: June 20, 2026
Author: Humanexa Intelligence
Therapeutic area: Pediatrics / Malnutrition
Asset: Trial
Trial SummaryCLN

Phase III

Pediatrics / Malnutrition

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

This trial represents a significant step in leveraging digital health interventions to address malnutrition among vulnerable populations. Its outcomes could reshape investment strategies in pediatric care and digital health solutions, particularly in low-resource settings.

Why it matters

This trial represents a significant step in leveraging digital health interventions to address malnutrition among vulnerable populations. Its outcomes could reshape investment strategies in pediatric care and digital health solutions, particularly in low-resource settings.

What changed

Trial Update

Analysis

A trial is underway to evaluate a two-way SMS platform aimed at improving nutritional outcomes for HIV-exposed children in Kenya.

This trial represents a significant step in leveraging digital health interventions to address malnutrition among vulnerable populations. Its outcomes could reshape investment strategies in pediatric care and digital health solutions, particularly in low-resource settings.

Monitor enrollment progress, interim results on malnutrition rates, and cost-effectiveness findings.

Related companies & assets

Assets

  • Trial →
  • HIV-exposed children in Kenya →

Sources & Humanexa intelligence

Source links

  • Trial of SMS Platform to Prevent Malnutrition in HIV-Exposed Children in Kenya ↗

Related Humanexa pages

  • Trial of SMS Platform to Prevent Malnutrition in HIV-Exposed Children in Kenya →

Related signals

Trial SummaryCLN

Phase III

esophageal squamous cell carcinoma (ESCC)

Status

Active

Sponsor

oncology therapeutics

Signal Score

8.4

Clinicalhigh signal

Lactobacillus reuteri promotes ferroptosis resistance in esophageal cancer via STAT3 lactylation

Lactobacillus reuteri induces D-lactate production, promoting STAT3 lactylation and reducing ferroptosis in ESCC.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / Colorectal Cancer

Status

Active

Signal Score

8.4

Clinicalhigh signal

Novel KRAS(G12V)-targeting peptide shows potent activity against colorectal cancer cells

Peptide-1 demonstrated strong binding affinity to KRAS G12V and potent antiproliferative effects in colorectal cancer cell lines.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.